European Medicines Agency Gives Positive Opinion on TiGenix’s Pediatric Investigation Plan For CD Perianal Fistulas Treatment
Crohn's Disease, News
Biopharmaceutical company TiGenix NV, which is currently developing and commercializing novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells (eASC’s) for inflammatory and autoimmune diseases, announced that it received ... Read more